Key facts
- It has raised $24.8M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include DH-LT Investments, German Accelerator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for AaviGen
- ·The full record, as it builds
Funding rounds
No funding rounds for AaviGen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AaviGen
Operator of a biotechnology company intended for cardiovascular and cardiopulmonary curative gene therapies. The company specializes in the development of curative gene remedies for genetic and acquired cardiovascular and cardiopulmonary diseases, enabling doctors to deliver therapeutic genes with unprecedented safety and precision to the diseased heart via a simple one-time intravenous injection.
- Sector
- Healthcare
- HQ
- Heidelberg, Germany
- Founded
- 2019
- Employees
- 11
- Website
- aavigen.com/
- Ownership
- Privately Held (backing)
AaviGen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AaviGen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AaviGen in its N-PORT filings yet. We sweep new filings monthly.